DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography (2015-2020)" report to their offering.
Pancreatic cancer is a disease in which cancer cells generate in the tissues of the pancreas. Globally, pancreatic cancer is the 12th most common cancer in men and 11th most common cancer in women. Addiction to cigarettes and health history are considered to be the foremost reasons increasing the risk.
The Global Pancreatic cancer market is expected to grow modestly from USD 1,730 million in 2015, at a CAGR of 10-17%.
Pancreatic cancer is a major challenge in the United States, where the 30,000 patients are diagnosed with the disease each year. The U.S. has the highest number of pancreatic cancer patients in the world. SEER estimates that there were 46,420 new pancreatic cancer cases chronicled in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, constituting 6.8 percent of the total cancer deaths in the US.
Companies Mentioned:
- Amgen
- Eli Lilly and Company
- Celgene Corporation
- Clovis Oncology
- Novartis AG
- Threshold Pharmaceuticals
- Incyte Corp
- Merrimack Pharmaceuticals
- Roche Ltd
-
NewLink Genetics
Report Structure:
1. Introduction
2. Executive Summary
3. Market Overview
4. Porters Five Force Analysis
5. Market Segmentation
6. Competitive Landscape
7. Company Profiles
8. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/wb25bq/global_pancreatic